Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
111In-TJD-31 SPECT Imaging in Solid Tumors
NCT07815951Phase 1Not yet recruiting
- Sponsor
- Yonghe Medical
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of 111In-TJD-31 in solid tumor (2 arms), sponsored by Yonghe Medical. Primary endpoints: Qualitative Assessment of Tumor Uptake by Visual Analysis and Semi-Quantitative Assessment of Tumor Uptake Using Standardized Uptake Value. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
111In-TJD-31
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07815951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815951.